Acquired In-Process Research and Development and Other Arrangements - Additional Information (Details)	1 Months Ended					3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Feb. 28, 2023 USD ($)	Jul. 31, 2022 USD ($)	May 31, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2019 USD ($) target
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Acquired in-process research and development expenses						$ 51,700,000	$ 29,000,000	$ 509,300,000	$ 92,900,000
Selling, general and administrative expenses						263,800,000	246,800,000	767,500,000	677,300,000
Septerna, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Asset acquisition, consideration transferred	$ 47,500,000
Catalyst Biosciences
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Asset acquisition, consideration transferred					$ 60,000,000
CRISPR Therapeutics
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, right to exclusively license, number of targets | target											3
Collaborative arrangement, development and regulatory potential milestone payments maximum											$ 410,000,000
CRISPR JDCA
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, development and regulatory potential milestone payments maximum										$ 200,000,000
Allocation of net profits and net losses, percent										60.00%
Research and development expenses						74,900,000	45,500,000	193,200,000	120,600,000
Selling, general and administrative expenses						26,000,000	$ 13,500,000	66,100,000	$ 35,300,000
CRISPR JDCA | CRISPR
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Allocation of net profits and net losses, percent										40.00%
CRISPR T1D
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Acquired in-process research and development expenses								170,000,000
Collaborative arrangement, development and regulatory potential milestone payments maximum								$ 160,000,000
Up-front payment		$ 100,000,000
Milestone payment						$ 70,000,000
Entrada Therapeutics
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, development and regulatory potential milestone payments maximum			$ 485,000,000
Up-front payment			225,100,000
Purchase of common stock			$ 24,900,000
Verve
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Up-front payment				$ 25,000,000
Purchase of common stock				$ 35,000,000